At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 268 enrolled
Drug / intervention
BMS-986165 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
In Brief
A Phase 2 clinical trial evaluating BMS-986165 and Placebo for BMS-986165 for Psoriasis. Completed, enrolled 268 participants across 76 sites in 8 countries.
Detailed Summary
A Study to evaluate efficacy and safety in subjects with moderate to severe Psoriasis treated with BMS-986165
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesAustralia, Canada, Germany, Japan, Latvia, Mexico, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartNov 2016
Primary CompletionNov 2017
TodayJul 2026
First PostedOct 13, 2016
Enrollment StartNov 15, 2016
Primary CompletionNov 16, 2017
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 9.7 years ago
Interventions
BMS-986165drug
Placebo for BMS-986165drug